Attachment 3. Summary of meningococcal conjugate vaccine recommendations, by risk group— Advisory Committee on Immunization Practices (ACIP), 2010. Risk group Primary series Booster dose Persons aged 11 through 18 1 dose, preferably At age 16 if primary years at dose age 11 or 12 at age 11 or 12 years Persons aged 11 through 18 1 dose, preferably At age 16 through 18 years if at primary age 11 or 12 years dose at age 13 through 15 years Persons aged 11 through 18 1 dose, preferably No booster needed if years at primary dose age 11 or 12 years on or after age 16 years HIV-infected persons in this 2 doses, 2 At age 16 years if primary age group months apart dose at age 11 or 12 years HIV-infected persons in this 2 doses, 2 At age 16 through 18 years if age group months apart primary dose at age 13 through 15 years HIV-infected persons in this 2 doses, 2 No booster needed if age group months apart primary dose on or after age 16 years Persons aged 2 through 55 2 2 months Every 5 years years with apart persistent complement component deficiency* or functional or anatomical asplenia Persons aged 2 through 55 2 doses, 2 At the earliest opportunity if with months apart a 1-dose persistent complement primary series administered, component then deficiency* or functional or every 5 years anatomical asplenia
Attachment 3. Summary of meningococcal conjugate vaccine recommendations, by risk group— Advisory Committee on Immunization Practices (ACIP), 2010. Risk group Primary series Booster dose Persons aged 11 through 18 years 1 dose, preferably at age 11 or 12 At age 16 if primary dose at age 11 or 12 years Persons aged 11 through 18 1 dose, preferably at age 11 or 12 years At age 16 through 18 years if primary dose at age 13 through 15 years Persons aged 11 through 18 years 1 dose, preferably at age 11 or 12 years No booster needed if primary dose on or after age 16 years HIV-infected persons in this age group 2 doses, 2 months apart At age 16 years if primary dose at age 11 or 12 years HIV-infected persons in this age group 2 doses, 2 months apart At age 16 through 18 years if primary dose at age 13 through 15 years HIV-infected persons in this age group 2 doses, 2 months apart No booster needed if primary dose on or after age 16 years Persons aged 2 through 55 years with persistent complement component deficiency* or functional or anatomical asplenia 2 2 months apart Every 5 years Persons aged 2 through 55 with persistent complement component deficiency* or functional or anatomical asplenia 2 doses, 2 months apart At the earliest opportunity if a 1-dose primary series administered, then every 5 years